TGTX and DTIL Related Headlines
Go Back- Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
- Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
- Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
TGTX and DTIL Related Press Releases
Go Back- Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
- Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
- Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
